Article
Multidisciplinary Sciences
Julius K. Demmer, Ben P. Phillips, O. Lisa Uhrig, Alain Filloux, Luke P. Allsopp, Maike Bublitz, Thomas Meier
Summary: This research elucidates the structure of F1Fo-ATP synthase in A. baumannii and reveals specific self-inhibition mechanism and structural adaptations in the proton-conducting pathway. These features may serve as attractive targets for the development of next-generation therapeutics.
Article
Infectious Diseases
Henan Li, Jiangang Zhang, Zhiren Wang, Yuyao Yin, Hua Gao, Ruobing Wang, Longyang Jin, Qi Wang, Chunjiang Zhao, Zhanwei Wang, Hui Wang
Summary: The within-host evolution of A. baumannii bacteremia is mainly driven by mutations, gene content changes, and limited effects of recombination. Genetic content diversity between different patients suggests an interplay of host and pathogen factors in within-host genetic diversity.
INFECTION AND DRUG RESISTANCE
(2021)
Article
Oncology
Adenilson de Souza da Fonseca, Andre Luiz Mencalha, Flavia de Paoli
Summary: A. baumannii is a pathogen of global importance with resistance to various antibiotics. Antimicrobial photodynamic therapy is considered a promising approach to overcome bacterial resistance, but further studies are needed to evaluate its effectiveness.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
(2021)
Article
Pediatrics
Capan Konca, Mehmet Tekin, Mehmet Geyik
Summary: The study investigated the antimicrobial resistance patterns of multidrug-resistant Acinetobacter baumannii in pediatric intensive care unit patients. Results showed that many previously effective drugs have lost their effectiveness against MDRAB, with colistin remaining as the only effective drug. New drugs and treatment protocols are urgently needed to combat MDRAB.
INDIAN JOURNAL OF PEDIATRICS
(2021)
Review
Immunology
Afreen Shadan, Avik Pathak, Ying Ma, Ranjana Pathania, Rajnish Prakash Singh
Summary: This article reviews the mechanisms, virulence factors, and other factors associated with the pathogenesis of A. baumannii infection. Additionally, it discusses the role of innate and adaptive immune response, as well as the current progress in developing innovative strategies to combat this multidrug-resistant pathogen.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Immunology
Tsung-Ta Chiang, Tzu-Wen Huang, Jun-Ren Sun, Shu-Chen Kuo, Aristine Cheng, Chang-Pan Liu, Yuag-Meng Liu, Ya-Sung Yang, Te-Li Chen, Yi-Tzu Lee, Yung-Chih Wang
Summary: This study investigated the impact of biofilm-forming Acinetobacter baumannii isolates on patients with bacteremia. The results showed that patients infected with biofilm-forming isolates exhibited different clinical features compared to non-biofilm-forming isolates, but the biofilm-forming ability was not an independent risk factor for 28-day mortality.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Infectious Diseases
T. Cebrero-Cangueiro, P. Nordmann, M. Carretero-Ledesma, J. Pachon, M. E. Pachon-Ibanez
Summary: The study demonstrated that meropenem was more effective than imipenem in treating carbapenem-resistant Acinetobacter baumannii infections in mice. The combination of meropenem and imipenem significantly improved the clearance of CRAb in the spleen. Dual carbapenem combination showed better efficacy in treating mice infected with carbapenemase-producing strains.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Pharmacology & Pharmacy
Joonhyeok Choi, Ahjin Jang, Young Kyung Yoon, Yangmee Kim
Summary: This study designed analogs of PapMA with Trp(18) showing the highest bacterial selectivity against CRAB and low cytotoxicity. PapMA-3 in combination with six selected antibiotics exhibited synergistic antibacterial activity against CRAB, providing a potential therapeutic approach against this pathogen.
Article
Microbiology
Shruti Kashyap, Prince Sharma, Neena Capalash
Summary: This study analyzed the transcriptome of A. baumannii ATCC 17978 after exposure to high concentration of tobramycin, revealing the potential molecular mechanism of tobramycin-induced cell death and identifying novel targets for further exploration.
CURRENT MICROBIOLOGY
(2022)
Article
Biology
Amit Gaurav, Varsha Gupta, Sandeep K. Shrivastava, Ranjana Pathania
Summary: Gaurav et al. report a synergistic interaction between nalidixic acid and tetracycline against multi-drug resistant bacteria Acinetobacter baumannii and Escherichia coli. They find that this synergy does not work for clinical isolates susceptible to antibiotics, suggesting the potential application of nalidixic acid and tetracycline against the emergence of multi-drug resistant bacteria.
COMMUNICATIONS BIOLOGY
(2021)
Article
Infectious Diseases
Yi Hong, Xiaochen Lin, Chunxu Zhang, Xingqiang Dong, Meihua Lu, Saihu Huang, Lili Huang, Chunmei Su, Zhenjiang Bai, Shuiyan Wu
Summary: This study retrospectively analyzed the demographic characteristics, clinical features, antibiotic susceptibility, and outcomes of 37 hospitalized children with laboratory-confirmed AB bacteremia in Suzhou, China. The study found that early clinical manifestations and indicators, such as elevated CRP and neutropenia, were associated with poor prognosis and could be independent predictors of mortality in children with AB bacteremia.
BMC INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Dongsub Kim, Haejeong Lee, Joon-sik Choi, Christina M. Croney, Ki-Sup Park, Hyo Jung Park, Joongbum Cho, Sohee Son, Jin Yeong Kim, Soo-Han Choi, Hee Jae Huh, Kwan Soo Ko, Nam Yong Lee, Yae-Jean Kim
Summary: This study retrospectively analyzed the epidemiological changes of Acinetobacter baumannii bacteremia in a pediatric ICU. The study found that Imipenem-resistant A. baumannii poses a serious threat to patients in the pediatric ICU.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2022)
Review
Infectious Diseases
Alemu Gedefie, Wondmagegn Demsis, Melaku Ashagrie, Yeshimebet Kassa, Melkam Tesfaye, Mihret Tilahun, Habtye Bisetegn, Zenawork Sahle
Summary: Acinetobacter species, especially A. baumannii, pose a significant threat in hospital environments, particularly in ICUs, due to their ability to develop antibiotic resistance mechanisms and cause biofilm-associated infections. Health care workers should focus on infection prevention and selective treatments to combat biofilm-related infections caused by A. baumannii.
INFECTION AND DRUG RESISTANCE
(2021)
Article
Multidisciplinary Sciences
Frits van Charante, David Martinez-Perez, Clara Guarch-Perez, Charlotte Courtens, Andrea Sass, Emilia Choinska, Joanna Idaszek, Serge Van Calenbergh, Martijn Riool, Sebastian A. J. Zaat, Wojciech Swieszkowski, Tom Coenye
Summary: In this study, the antimicrobial activity of the fosmidomycin prodrug CC366 against Acinetobacter baumannii was evaluated. The results showed that CC366 exhibited good bacteriostatic and anti-biofilm activity against A. baumannii. Additionally, a 3D-printed wound dressing incorporating CC366 successfully prevented A. baumannii infection.
Article
Infectious Diseases
Xingchen Bian, Xiaofen Liu, Meiqing Feng, Phillip J. Bergen, Jian Li, Yuancheng Chen, Huajun Zheng, Sichao Song, Jing Zhang
Summary: This study conducted whole genome sequencing on carbapenem-resistant Acinetobacter baumannii isolates and investigated the bacterial killing effects of colistin and sulbactam combination therapy. The results showed that higher sulbactam concentration and longer infusion time substantially enhanced bacterial killing in a dynamic model.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Article
Infectious Diseases
Guan-Jhou Chen, Hsin-Yun Sun, Ling-Ya Chen, Szu-Min Hsieh, Wang-Hui Sheng, Wang-Da Liu, Yu-Chung Chuang, Yu-Shan Huang, Kuan-Yin Lin, Pei-Ying Wu, Hsi-Yen Chang, Yu-Zhen Luo, Yi-Ching Su, Wen-Chun Liu, Sui-Fang Chang, Sui-Yuan Chang, Chien-Ching Hung
Summary: This study investigated the incidence and impact of low-level viraemia (LLV) among HIV-infected patients receiving second-generation integrase strand transferase inhibitors. The results showed that the risk of developing LLV or virologic failure (VF) was similar after switching to either dolutegravir- or bictegravir-based antiretroviral therapy (ART) in virally suppressed patients. Pre-existing resistance-associated mutations or LLV events were not associated with subsequent VF.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2022)
Article
Medicine, General & Internal
Wang-Huei Sheng, Chung-Cheng Wang, Ching -Chi Chu, Yueh-Juh Lin, Sui-Yuan Chang, Shan-Chwen Chang
Summary: We reported the clinical and immunological effects of undiluted BNT162b2 vaccine inoculation in 25 recipients. The most common adverse reactions were injection site pain, fever, fatigue, chest tightness, and dizziness. Laboratory abnormalities included anemia and elevated liver transaminase level. These adverse reactions and abnormalities were mild and spontaneously recovered within a few weeks. The spike IgG titers significantly increased after a booster dose of BNT162b2.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, Research & Experimental
Yu-Chung Chuang, Hsin-Yi Lin, Jann-Tay Wang, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Huang, Yee-Chun Chen, Shan-Chwen Chang
Summary: This retrospective cohort study compares different daptomycin minimum inhibitory concentration (MIC) testing methods for predicting clinical outcome of vancomycin-resistant enterococcus (VRE) bacteremia. The results indicate that the dichotomized threshold for free drug area under the concentration-time curve to MIC ratio (fAUC/MIC) for broth microdilution (BMD) is the best predictor of mortality.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Immunology
Chun-Fu Huang, Jann-Tay Wang, Yu -Chung Chuang, Wang-Huei Sheng, Yee -Chun Chen
Summary: This study evaluated the in vitro activity of eravacycline against common Enterobacterales and found that it exhibited high susceptibility rates against certain strains, making it a potential therapeutic option.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2023)
Article
Medicine, General & Internal
Wang-Huei Sheng, Sui-Yuan Chang, Ming-Ju Hsieh, Si-Man Ieong, Shan-Chwen Chang
Summary: The appropriate interval between heterologous prime adenoviral vectored vaccination and boost mRNA vaccination remains unclear. We recruited 100 adult participants to receive a prime adenoviral vectored vaccine (ChAdOx1, AstraZeneca) and a boost mRNA vaccine (mRNA-1273, Moderna) 12 weeks apart and checked their serum SARS-CoV-2 anti-spike IgG titers and neutralizing antibody titers against B.1.1.7 (alpha) and B.1.617.2 (delta) variants on the 28th day after the boost dose. Results were compared with our previous study cohorts who received the same prime-boost vaccinations at 4-and 8-week intervals. Compared to other heterologous vaccination groups, the 12-week interval group had higher neutralizing antibody titers against SARS-CoV-2 variants than the 4-week interval group and was similar to the 8-week interval group at day 28. Adverse reactions after the boost dose were mild and transient. Our results support deploying viral vectored and mRNA vaccines in a flexible schedule with intervals from 8 to 12 weeks.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
Wang-Huei Sheng, Si-Man Ieong, Pin-Hung Lin, Ming-Ju Hsieh, Hung-Chih Yang, Ching-Fu Pan, Tai-Ling Chao, Sui-Yuan Chang, Shan-Chwen Chang
Summary: The study investigated the immunogenicity and adverse events of the third dose of mRNA vaccines in healthy adults. The results showed that the third dose mRNA COVID-19 vaccines markedly enhanced cellular and humoral responses and were safe. Immunological responses and adverse events were higher in individuals receiving the full-dose mRNA-1273 vaccine compared to other groups.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Article
Infectious Diseases
Szu-Ting Huang, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Hang, Jann-Tay Wang, Yu-Chung Chuang, Yee-Chun Chen, Shan-Chwen Chang
Summary: This study analyzed the risk factors affecting the treatment outcome of linezolid for vancomycin-resistant Enterococcus bloodstream infection. The study found that the linezolid minimum inhibitory concentration and concentration-time curve/MIC were not associated with mortality, while the linezolid dose per body weight, body height, and the interaction between them were independent risks for mortality. In conclusion, the clinical outcomes of linezolid treatment for vancomycin-resistant Enterococcus bloodstream infection are associated with the dose and body height.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Aristine Cheng, Ming-Ju Hsieh, Sui-Yuan Chang, Si-Man Ieong, Chien-Yu Cheng, Wang-Huei Sheng, Shan-Chwen Chang
Summary: This study investigated whether adverse reactions to different COVID-19 vaccines reliably predict immune responses. The results showed that participants who reported local erythema, swelling, pain, as well as systemic fever, chills, headache, myalgia, arthralgia, and fatigue had significantly higher antibody levels at days 14 and 28 compared to those who did not report local or systemic reactogenicity.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Article
Infectious Diseases
Tai-Chung Tseng, Yu-Chung Chuang, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Huang, Jann-Tay Wang, Yee-Chun Chen, Shan-Chwen Chang
Summary: In this study, combination therapy with high-dose daptomycin and fosfomycin was found to improve the survival rate of patients with vancomycin-resistant enterococcus bloodstream infection compared to daptomycin monotherapy. The survival benefit was most pronounced for patients with fosfomycin MIC ≤64 mg/L and a low Pitt bacteremia score.
INFECTIOUS DISEASES AND THERAPY
(2023)
Article
Immunology
Guan-Jhou Chen, Hsin-Yun Sun, Kuan-Yin Lin, Szu-Min Hsieh, Yu-Chung Chuang, Wang-Da Liu, Yu-Shan Huang, Sung-Ching Pan, Un-In Wu, Aristine Cheng, Yi-Chia Huang, Cheng-Hsin Wu, Yi-Ching Su, Wen-Chun Liu, Sui-Yuan Chang, Chien-Ching Hung
Summary: For people with human immunodeficiency virus (PWH) who had no response or seroreversion after primary hepatitis A virus (HAV) vaccination, an accelerated 2-dose revaccination (vs 1-dose) produced higher antibody titers and elicited a higher serological response rate at week 48 for nonresponders.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Ling-Ya Chen, Hsin-Yun Sun, Yu -Chung Chuang, Wang -Da Liu, Kuan-Yin Lin, Hsi -Yen Chang, Yu-Zhen Luo, Pei-Ying Wu, Yi-Ching Su, Wen -Chun Liu, Chien -Ching Hung
Summary: This study aimed to investigate the improvement in HIV-related symptom burden among people living with HIV (PLWH) who switched to the co-formulated bic-tegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) in a real-world setting. The results showed that after 48 weeks of switching to B/F/TAF, there was a significant reduction in the prevalence and bothersomeness of certain symptoms.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2023)
Article
Immunology
Hsin-Yun Sun, Bo-Huang Liou, Tun-Chieh Chen, Chia-Jui Yang, Sung-Hsi Huang, Po-Liang Lu, Chung-Hao Huang, Mao-Song Tsai, Shu-Hsing Cheng, Nan-Yao Lee, Wen-Chien Ko, Yen-Hsu Chen, Wang-Da Liu, Shang-Yi Lin, Shih-Ping Lin, Po-Lin Chen, Ling-Shan Syue, Yu-Shan Huang, Yu-Chung Chuang, Cheng-Bin Chen, Ya-Ting Chang, Yuan-Ti Lee, Szu-Min Hsieh, Li-Hsin Su, Chien-Yu Cheng, Chien-Ching Hung
Summary: Using 3-stage pooled-plasma hepatitis C virus (HCV) RNA testing performed quarterly among at-risk people with human immunodeficiency virus (PWH), we found that if testing had been performed every 6 or 12 months, 58.6%-91.7% of PWH who recently acquired HCV would be delayed for diagnosis and might contribute to onward HCV transmission with longer durations.
OPEN FORUM INFECTIOUS DISEASES
(2023)
Article
Microbiology
Kai-Hsiang Chen, Wang-Da Liu, Hsin-Yun Sun, Kuan-Yin Lin, Szu-Min Hsieh, Wang-Huei Sheng, Yu-Chung Chuang, Yu-Shan Huang, Aristine Cheng, Chien-Ching Hung
Summary: Limited studies have been conducted on immune reconstitution inflammatory syndrome (IRIS) in people living with HIV (PLWH) who present with interstitial pneumonitis (IP), particularly in the era of rapid antiretroviral therapy (ART) initiation with integrase strand-transfer inhibitor (INSTI)-containing regimens. A retrospective study identified PLWH who were diagnosed with IP and initiated ART within 30 days. The study found a high rate of IRIS and associations with baseline immune depletion, rapid decline of plasma HIV RNA load, and rapid initiation of ART.
MICROBIOLOGY SPECTRUM
(2023)
Article
Immunology
Guan-Jhou Chen, Hsin-Yun Sun, Sui-Yuan Chang, Szu-Min Hsieh, Wang-Hui Sheng, Yu-Chung Chuang, Yu-Shan Huang, Kuan-Yin Lin, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung
Summary: This study aimed to investigate the virologic suppression effectiveness of switching to dolutegravir-based regimens or BIC/FTC/TAF among HIV-infected individuals who experienced viral rebound during other antiretroviral therapy. The results showed that within the first 48 weeks after switching, both dolutegravir-based regimens and BIC/FTC/TAF could achieve viral suppression in approximately four-fifths of the patients, and pre-existing NRTI-related resistance-associated mutations did not have a negative impact on the effectiveness.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2023)
Article
Multidisciplinary Sciences
Christopher H. Gu, Layla A. Khatib, Ayannah S. Fitzgerald, Jevon Graham-Wooten, Caroline A. Ittner, Scott Sherrill-Mix, Yuchung Chuang, Laurel J. Glaser, Nuala J. Meyer, Frederic D. Bushman, Ronald G. Collman
Summary: This study used sequencing analysis to investigate the relationship between gut microbiome and bloodstream infection in critically ill patients. The results showed that gut microbiome constituents matching the bloodstream infection species were present in half of the cases, with strain-level identity depending on the relative abundance of the species in the gut.